Axel Stenmark Tullberg1, Reidunn Jetne Edelmann2, Erik Holmberg1, Arne Östman3, Carina Strell3, Lars Andreas Akslen2, Per Malmström4,5, Mårten Fernö4, Per Karlsson6. 1. Department of Oncology, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway. 3. Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 4. Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. 5. Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 6. Department of Oncology, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. per.karlsson@oncology.gu.se.
Abstract
PURPOSE: Predictive biomarkers are needed to aid the individualization of radiotherapy (RT) in breast cancer. Cancer-associated fibroblasts have been implicated in tumor radioresistance and can be identified by platelet-derived growth factor receptor-beta (PDGFRb). This study aims to analyze how PDGFRb expression affects RT benefit in a large randomized RT trial. METHODS:PDGFRb was assessed by immunohistochemistry on tissue microarrays from 989 tumors of the SweBCG91RT trial, which enrolled lymph node-negative, stage I/IIA breast cancer patients randomized to RT after breast-conserving surgery. Outcomes were analyzed at 10 years for ipsilateral breast tumor recurrence (IBTR) and any recurrence and 15 years for breast cancer specific death (BCSD). RESULTS:PDGFRb expression correlated with estrogen receptor negativity and younger age. An increased risk for any recurrence was noted in univariable analysis for the medium (HR 1.58, CI 95% 1.11-2.23, p = 0.011) or PDGFRb high group (1.49, 1.06-2.10, p = 0.021) compared to the low group. No differences in IBTR or BCSD risk were detected. RT benefit regarding IBTR risk was significant in the PDGFRb low (0.29, 0.12-0.67, p = 0.004) and medium (0.31, 0.16-0.59, p < 0.001) groups but not the PDGFRb high group (0.64, 0.36-1.11, p = 0.110) in multivariable analysis. Likewise, risk reduction for any recurrence was less pronounced in the PDGFRb high group. No significant interaction between RT and PDGFRb-score could be detected. CONCLUSION: A higher PDGFRb-score conferred an increased risk of any recurrence, which partly can be explained by its association with estrogen receptor negativity and young age. Reduced RT benefit was noted among patients with high PDGFRb, however without significant interaction.
RCT Entities:
PURPOSE: Predictive biomarkers are needed to aid the individualization of radiotherapy (RT) in breast cancer. Cancer-associated fibroblasts have been implicated in tumor radioresistance and can be identified by platelet-derived growth factor receptor-beta (PDGFRb). This study aims to analyze how PDGFRb expression affects RT benefit in a large randomized RT trial. METHODS:PDGFRb was assessed by immunohistochemistry on tissue microarrays from 989 tumors of the SweBCG91RT trial, which enrolled lymph node-negative, stage I/IIA breast cancerpatients randomized to RT after breast-conserving surgery. Outcomes were analyzed at 10 years for ipsilateral breast tumor recurrence (IBTR) and any recurrence and 15 years for breast cancer specific death (BCSD). RESULTS:PDGFRb expression correlated with estrogen receptor negativity and younger age. An increased risk for any recurrence was noted in univariable analysis for the medium (HR 1.58, CI 95% 1.11-2.23, p = 0.011) or PDGFRb high group (1.49, 1.06-2.10, p = 0.021) compared to the low group. No differences in IBTR or BCSD risk were detected. RT benefit regarding IBTR risk was significant in the PDGFRb low (0.29, 0.12-0.67, p = 0.004) and medium (0.31, 0.16-0.59, p < 0.001) groups but not the PDGFRb high group (0.64, 0.36-1.11, p = 0.110) in multivariable analysis. Likewise, risk reduction for any recurrence was less pronounced in the PDGFRb high group. No significant interaction between RT and PDGFRb-score could be detected. CONCLUSION: A higher PDGFRb-score conferred an increased risk of any recurrence, which partly can be explained by its association with estrogen receptor negativity and young age. Reduced RT benefit was noted among patients with high PDGFRb, however without significant interaction.
Entities:
Keywords:
Early breast cancer; Fibroblasts; PDGFR; Radiotherapy; Tumor microenvironment
Authors: Anikó Kovács; Axel Stenmark Tullberg; Elisabeth Werner Rönnerman; Erik Holmberg; Linda Hartman; Martin Sjöström; Dan Lundstedt; Per Malmström; Mårten Fernö; Per Karlsson Journal: J Clin Oncol Date: 2019-04-02 Impact factor: 44.544
Authors: Oliver Frings; Martin Augsten; Nicholas P Tobin; Joseph Carlson; Janna Paulsson; Cristina Pena; Eleonor Olsson; Srinivas Veerla; Jonas Bergh; Arne Ostman; Erik L L Sonnhammer Journal: Am J Pathol Date: 2013-04-10 Impact factor: 4.307
Authors: F Killander; P Karlsson; H Anderson; J Mattsson; E Holmberg; D Lundstedt; L Holmberg; P Malmström Journal: Eur J Cancer Date: 2016-09-07 Impact factor: 9.162
Authors: Janna Paulsson; Lisa Rydén; Carina Strell; Oliver Frings; Nicholas P Tobin; Tommy Fornander; Jonas Bergh; Göran Landberg; Olle Stål; Arne Östman Journal: J Pathol Clin Res Date: 2016-09-14
Authors: Sara Jansson; Kristina Aaltonen; Pär-Ola Bendahl; Anna-Karin Falck; Maria Karlsson; Kristian Pietras; Lisa Rydén Journal: Breast Cancer Res Treat Date: 2018-01-29 Impact factor: 4.872